<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">McKenney, James M.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">New Monoclonal Antibody to PCSK9 Markedly Lowers LDL-C in Patients on Atorvastatin</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">Proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) binds to low-density lipoprotein receptors (LDLRs) and plays a pivotal role in LDLR degradation [McKenney JM et al. J Am Coll Cardiol 2012]. This article discusses outcomes on the low-density lipoprotein cholesterol-lowering effects of SAR236553/REGN727 (SAR236553), a highly specific, fully human monoclonal antibody to PCSK9 [Efficacy and Safety Evaluation of SAR236553 (REGN727) In Patients With Primary Hypercholesterolemia and LDL-Cholesterol on Stable Atorvastatin Therapy; NCT01288443].</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>